Overview
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic MYBPC3 mutation-associated nonobstructive hypertrophic cardiomyopathy (nHCM).
Description
The study will consist of 2 escalating dose cohorts. The study will enroll at least 6 and as many as 15 patients. All patients will receive active drug. The study will follow patients for 5 years following a single dose of TN-201.
Eligibility
Inclusion Criteria:
- MYBPC3 mutation
- Nonobstructive Hypertrophic Cardiomyopathy
- Left Ventricular Ejection Fraction ≥50%
- Functioning Implantable Cardiac Defibrillator
- NYHA Functional Class II or III symptoms
- NT-proBNP ≥300pg/ml
Exclusion Criteria:
- High AAV9 neutralizing antibody titer